3 results
Approved WMOCompleted
The primary objective of this study is to determine the effect of once-daily oral MGL-3196 60 mgor 100 mg versus placebo for 12 weeks on the percent change from baseline in low-densitylipoprotein cholesterol (LDL-C) in patients with HeFH.The…
Approved WMOCompleted
The primary objective is to evaluate the efficacy of daratumumab in addition to standard chemotherapy in relapsed/refractory B-cell acute lymphoblastic leukemia (ALL) and T-cell ALL as measured by the complete response (CR) rate.The secondary…
Approved WMOCompleted
* To establish the safety profile of daratumumab when given in combination with lenalidomide and dexamethasone in subjects with relapsed or relapsed and refractory MM